Pass pharma discounts onto patients, not 'highly-paid middlemen', says expert

21 May 2018

The part that pharmacy benefit managers (PBMs), insurers and pharmacies play in increasing the prices that patients pay for their medicines was the focus of a panel discussion last week.

Merrill Matthews, resident scholar of the Institute of Policy Innovation, and Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest, took part in the discussion hosted by the Mackinac Center for Public Policy in Lansing to consider the various solutions being weighed in Michigan.

"Health insurers have increasingly raised out-of-pocket costs, especially for the newest and most innovative drugs"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK